The Efficacy of Two Specific Toll-like Receptor 4 Antagonists (G2013 & M2000) in Clinical Inflammatory Disease
DOI:
https://doi.org/10.14738/bjhmr.106.14305Keywords:
Toll-like receptor 4, Mannuronic acid, Guluronic acid, InflammationAbstract
Toll-like receptors (TLRs) are receptors of the innate immune system that detect pathogen-associated molecular patterns and endogenous “danger” molecules. Among the family, the fundamental role of Toll-like receptor 4 (TLR 4) has been underscored in the initiation of pro-inflammatory cellular signaling pathways. Therefore, the appropriate suppression of Toll-like receptor 4 signaling is vital to maintain the balance between autoimmunity and inflammatory responses to avoid detrimental effects caused by the host immune system. This paper reviewed the structure of TLRs and their essential role in inflammation, specifically Toll-like receptor 4, its signaling cascade, and its antagonists. Recently, using two new drugs, M2000 (β-D-Mannuronic acid) and G2013 (α-L-Guluronic acid), the novel Toll-like receptor 4 antagonists are proposed to control inflammatory conditions. Immunosuppressive and anti-inflammatory properties of M2000 and G2013 have been examined in invitro, pre-clinical, and clinical trial studies. Experimental and clinical studies on these drugs revealed TLR4 antagonistic properties with significant efficacy for controlling inflammatory responses and treating autoimmune diseases.
References
Zhu, J. and C. Mohan, Toll-like receptor signaling pathways—therapeutic opportunities. Mediators of inflammation, 2010. 2010.
Pandolfi, F., et al., Key role of DAMP in inflammation, cancer, and tissue repair. Clinical therapeutics, 2016.
Barton, G.M. and J.C. Kagan, A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nature Reviews Immunology, 2009. 9(8): p. 535-542.
Mortazavi-Jahromi, S.S., et al., Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway. International Immunopharmacology, 2018. 55: p. 323-329.
Laird, M.H., et al., TLR4/MyD88/PI3K interactions regulate TLR4 signaling. Journal of leukocyte biology, 2009. 85(6): p. 966-977.
Chen, C.-Y., C.-L. Kao, and C.-M. Liu, the cancer prevention, anti-inflammatory and anti-oxidation of bioactive phytochemicals targeting the TLR4 signaling pathway. International journal of molecular sciences, 2018. 19(9): p. 2729.
Wu, Y.-w., W. Tang, and J.-p. Zuo, Toll-like receptors: potential targets for lupus treatment. Acta Pharmacologica Sinica, 2015. 36(12): p. 1395-1407.
Calich, V.L., et al., Toll-like receptors and fungal infections: the role of TLR2, TLR4 and MyD88 in paracoccidioidomycosis. FEMS Immunology & Medical Microbiology, 2008. 53(1): p. 1-7.
Lee, C.C., A.M. Avalos, and H.L. Ploegh, Accessory molecules for Toll-like receptors and their function. Nature Reviews Immunology, 2012. 12(3): p. 168-179.
McClure, R. and P. Massari, TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Frontiers in immunology, 2014. 5: p. 386.
Marongiu, L., et al., Below the surface: The inner lives of TLR4 and TLR9. Journal of leukocyte biology, 2019. 106(1): p. 147-160.
Akira, S., S. Uematsu, and O. Takeuchi, Pathogen recognition and innate immunity. Cell, 2006. 124(4): p.
Lavelle, E.C., et al., The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis. Mucosal immunology, 2010. 3(1): p. 17-28.
Kawai, T. and S. Akira, The roles of TLRs, RLRs and NLRs in pathogen recognition. International
Bell, J.K., et al., Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends in
O'Neill, L.A. and A.G. Bowie, The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology, 2007. 7(5): p. 353-364.
Hosseini, A.M., et al., Toll-like receptors in the pathogenesis of autoimmune diseases. Advanced pharmaceutical bulletin, 2015. 5(Suppl 1): p. 605.
O'Neill, L.A., et al., Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors. Journal of endotoxin research, 2003. 9(1): p. 55-59.
Liu, Y., et al., TLR2 and TLR4 in autoimmune diseases: a comprehensive review. Clinical reviews in allergy & immunology, 2014. 47(2): p. 136-147.
Kawasaki, T. and T. Kawai, Toll-like receptor signaling pathways. Frontiers in immunology, 2014. 5: p. 461.
Wu, K., et al., TLR4/MyD88 signaling determines the metastatic potential of breast cancer cells. Molecular medicine reports, 2018. 18(3): p. 3411-3420. 311
Wang, L., et al., Dual functional roles of the MyD88 signaling in colorectal cancer development. Biomedicine & Pharmacotherapy, 2018. 107: p. 177-184.
Johnson, R.H., et al., The functional and inflammatory response of brain endothelial cells to toll-like receptor agonists. Scientific reports, 2018. 8(1): p. 1-12.
Dajon, M., K. Iribarren, and I. Cremer, Toll-like receptor stimulation in cancer: a pro-and anti-tumor double-edged sword. Immunobiology, 2017. 222(1): p. 89-100.
Balistreri, C.R., et al., Role of TLR polymorphisms in immunosenescence, in Handbook on Immunosenescence. 2009, Springer. p. 659-671.
Balistreri, C.R., et al., TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases. Journal of clinical immunology, 2009. 29(4): p. 406-415.
Kaisho, T. and S. Akira, Dendritic-cell function in Toll-like receptor-and MyD88-knockout mice. Trends in
Medzhitov, R., P. Preston-Hurlburt, and C.A. Janeway, A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 1997. 388(6640): p. 394-397.
Matsunaga, N., et al., TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules. Molecular pharmacology, 2011. 79(1): p. 34-41.
Opal, S.M. and C.T. Esmon, Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Critical Care, 2002. 7(1): p. 23.
Jenkins, K.A. and A. Mansell, TIR-containing adaptors in Toll-like receptor signalling. Cytokine, 2010. 49(3): p. 237-244.
Park, B.S., et al., The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature, 2009. 458(7242): p. 1191-1195.
Molteni, M., S. Gemma, and C. Rossetti, The role of toll-like receptor 4 in infectious and noninfectious inflammation. Mediators of inflammation, 2016. 2016.
Kagan, J.C., et al., TRAM couples’ endocytosis of Toll-like receptor 4 to the induction of interferon-β. Nature
Kuzmich, N.N., et al., TLR4 signaling pathway modulators as potential therapeutics in inflammation and sepsis. Vaccines, 2017. 5(4): p. 34.
Mai, C.W., Y.B. Kang, and M.R. Pichika, should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. OncoTargets and therapy, 2013. 6: p. 1573.
Dauphinee, S.M. and A. Karsan, Lipopolysaccharide signaling in endothelial cells. Laboratory investigation, 2006. 86(1): p. 9-22.
Kumar, V., Innate lymphoid cells: new paradigm in immunology of inflammation. Immunology letters, 2014. 157(1-2): p. 23-37.
Lucas, K. and M. Maes, Role of the Toll Like receptor (TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Molecular neurobiology, 2013. 48(1): p. 190-204. 312
Thomas, L., et al., The N-terminus of CD14 acts to bind apoptotic cells and confers rapid-tethering capabilities on non-myeloid cells. PLoS One, 2013. 8(7): p. e70691.
Huang, J.-M., et al., Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway. Scientific reports, 2014. 4: p. 3840.
Takeda, K. and S. Akira, Toll-like receptors in innate immunity. International immunology, 2005. 17(1): p.
Perros, F., B.N. Lambrecht, and H. Hammad, TLR4 signalling in pulmonary stromal cells is critical for inflammation and immunity in the airways. Respiratory research, 2011. 12(1): p. 1-8.
Noulin, N., et al., Both hemopoietic and resident cells are required for MyD88-dependent pulmonary inflammatory response to inhaled endotoxin. The Journal of Immunology, 2005. 175(10): p. 6861-6869.
Brubaker, S.W., et al., Innate immune pattern recognition: a cell biological perspective. Annual review of immunology, 2015. 33: p. 257-290.
Takeda, K. and S. Akira, Microbial recognition by Toll-like receptors. Journal of dermatological science, 2004. 34(2): p. 73-82.
Tobias, P. and L.K. Curtiss, Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. Journal of lipid research, 2005. 46(3): p. 404-411.
Andreakos, E., et al., The toll-like receptor-nuclear factor kappaB pathway in rheumatoid arthritis. Front Biosci, 2005. 10: p. 2478-2488.
Schmidt, M., et al., Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nature immunology, 2010. 11(9): p. 814-819.
Wu, F.-x., et al., Intrathecal siRNA against Toll-like receptor 4 reduces nociception in a rat model of neuropathic pain. International journal of medical sciences, 2010. 7(5): p. 251.
Tsung, A., et al., Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. The Journal of Immunology, 2005. 175(11): p. 7661-7668.
Powers, K.A., et al., Oxidative stress generated by hemorrhagic shock recruits Toll-like receptor 4 to the plasma membrane in macrophages. The Journal of experimental medicine, 2006. 203(8): p. 1951-1961.
Alfonso-Loeches, S., et al., Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. Journal of Neuroscience, 2010. 30(24): p. 8285-8295.
Kolek, M.J., et al., Toll–like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. American heart journal, 2004. 148(6): p. 1034-1040.
Garcia–Rodriguez, S., et al., Increased gene expression of Toll‐like receptor 4 on peripheral blood mononuclear cells in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2013. 27(2): p. 242-250.
Shaw, P.J., et al., Signaling via the RIP2 adaptor protein in central nervous system-infiltrating dendritic cells promotes inflammation and autoimmunity. Immunity, 2011. 34(1): p. 75-84.
Devaraj, S., et al., Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism, 2011. 60(2): p. 256-259. URL: http://dx.doi.org/10.14738/bjhmr.106.14305. 313
Roozbehkia, M., et al., The potent suppressive effect of β-d-mannuronic acid (M2000) on molecular expression of the TLR/NF-kB signaling pathway in ankylosing spondylitis patients. International immunopharmacology, 2017. 52: p. 191-196.
Kuang, X., et al., Effects of intrathecal epigallocatechin gallate, an inhibitor of Toll-like receptor 4, on chronic neuropathic pain in rats. European journal of pharmacology, 2012. 676(1-3): p. 51-56.
Kanuri, G., et al., Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. The Journal of nutrition, 2009. 139(3): p. 482-487.
Apetoh, L., et al., Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature medicine, 2007. 13(9): p. 1050-1059.
Wang, L. and J. Chen, Progress in studies on TLR4 signaling pathway and major depressive disorder. Zhong nan da xue xue bao. Yi xue ban= Journal of Central South University. Medical Sciences, 2017. 42(6): p. 725-
Abdollahi‐Roodsaz, S., et al., Inhibition of Toll‐like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2007. 56(9): p. 2957-2967.
Fekonja, O., M. Avbelj, and R. Jerala, Suppression of TLR signaling by targeting TIR domain-containing proteins. Current Protein and Peptide Science, 2012. 13(8): p. 776-788.
Yamamoto, M. and S. Akira, Lipid A receptor TLR4-mediated signaling pathways, in Lipid A in Cancer Therapy. 2009, Springer. p. 59-68.
Takeuchi, O. and S. Akira, Pattern recognition receptors and inflammation. Cell, 2010. 140(6): p. 805-820.
Yamamoto, M. and K. Takeda, Current views of toll-like receptor signaling pathways. Gastroenterology research and practice, 2010. 2010.
Liew, F.Y., et al., Negative regulation of toll-like receptor-mediated immune responses. Nature Reviews
Kawai, T. and S. Akira, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nature immunology, 2010. 11(5): p. 373.
Sharifi, L., et al., The Inhibitory Role of M2000 (β-D-Mannuronic Acid) on Expression of Toll-like Receptor 2 and 4 in HT29 Cell Line. Recent patents on inflammation & allergy drug discovery, 2019. 13(1): p. 57-65.
Földes, G., et al., Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. International journal of cardiology, 2008. 124(1): p. 80-85.
Fang, D., et al., Atorvastatin suppresses Toll-like receptor 4 expression and NF-kappaB activation in rabbit atherosclerotic plaques. Eur Rev Med Pharmacol Sci, 2014. 18(2): p. 242-246.
Methe, H., et al., Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arteriosclerosis, thrombosis, and vascular biology, 2005. 25(7): p. 1439-1445.
Zhang, G. and S. Ghosh, Negative regulation of toll-like receptor-mediated signaling by Tollip. Journal of Biological Chemistry, 2002. 277(9): p. 7059-7065.
Didierlaurent, A., et al., Tollip regulates proinflammatory responses to interleukin-1 and lipopolysaccharide. Molecular and cellular biology, 2006. 26(3): p. 735-742. 314
Loiarro, M., et al., Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound. Journal of leukocyte biology, 2007. 82(4): p. 801-810.
Narayanan, K.B. and H.H. Park, Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis, 2015. 20(2): p. 196-209.
Taganov, K.D., et al., NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences, 2006. 103(33): p.
Boldin, M.P., et al., miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. The Journal of experimental medicine, 2011. 208(6): p. 1189-1201.
Babazada, H., F. Yamashita, and M. Hashida, Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4–NF-κB signaling. Journal of controlled release, 2014. 194: p. 295-300.
Slivka, P.F., et al., A peptide antagonist of the TLR4–MD2 interaction. Chembiochem, 2009. 10(4): p. 645-
Spiller, S., et al., TLR4-induced IFN-γ production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. The Journal of experimental medicine, 2008. 205(8): p. 1747-1754.
Monnet, E., et al., AB0451 NI-0101, a monoclonal antibody targeting toll like receptor 4 (TLR4) being developed for rheumatoid arthritis (RA) treatment with a potential for personalized medicine. 2015, BMJ Publishing Group Ltd.
Kashefi, S., et al., A randomized, controlled, phase II clinical trial of β‐D‐mannuronic acid (M2000) in pre‐surgical breast cancer patients at early stage (T1‐T2). Clinical and Experimental Pharmacology and Physiology, 2019. 46(6): p. 527-532.
Mirshafiey, A., et al., Treatment of experimental arthritis with M2000, a novel designed non‐steroidal anti‐inflammatory drug. Scandinavian journal of immunology, 2005. 61(5): p. 435-441.
Mirshafiey, A., et al., Production of M2000 (β-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environmental toxicology and pharmacology, 2007. 24(1): p. 60-66.
Mortazavi‐Jahromi, S.S., et al., Immunopharmacological effect of β‐d‐mannuronic acid (M2000), as a new immunosuppressive drug, on gene expression of miR‐155 and its target molecules (SOCS1, SHIP1) in a clinical trial on rheumatoid arthritis patients. Drug Development Research, 2020. 81(3): p. 295-304.
Gaafar, N.A., A. Razavi, and A. Mirshafiey, β-D-Mannuronic Acid (M2000) as a landmark in Pharmacology. Current drug discovery technologies, 2019.
Klaver, E., et al., Trichuris suis soluble products induce Rab7b expression and limit TLR4 responses in human dendritic cells. Genes & Immunity, 2015. 16(6): p. 378-387.
Aletaha, S., et al., M2000 (β‐d‐mannuronic acid) as a novel antagonist for blocking the TLR 2 and TLR 4 downstream signalling pathway. Scandinavian journal of immunology, 2017. 85(2): p. 122-129.
Bakhtiari, T., et al., An in vitro assessment for evaluating the efficiency of β‐d‐mannuronic acid (M2000) in myelodysplastic syndrome. Journal of cellular physiology, 2019. 234(8): p. 12971-12977.
Mirshafiey, A., et al., Introduction of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/COX-2 activity and gene expression. Pharmacological reports, 2017. 69(5): p. 1067-1072. 315
Taeb, M., et al., Effect of β-d-mannuronic acid (M2000) on oxidative stress enzymes’ gene using healthy donor peripheral blood mononuclear cells for evaluating the anti-aging property. Current drug discovery technologies, 2019. 16(3): p. 265-271.
Sharifi, L., et al., Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-ΚB in HEK293 TLR2 and HEK293 TLR4. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders), 2019. 19(2): p. 144-
Mortazavi-Jahromi, S.S., et al., Pharmacological effects of β-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-κB gene expression, as target molecules in inflammatory reactions. Pharmacological reports, 2017. 69(3): p. 479-484.
Mirshafiey, A., et al., M2000: a revolution in pharmacology. Medical science monitor, 2005. 11(8): p. PI53-PI63.
Mirshafiey, A., et al., Novel immunosuppressive therapy by M2000 in experimental multiple sclerosis. Immunopharmacology and immunotoxicology, 2005. 27(2): p. 255-265.
Fattahi, M.J., et al., Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal antiinflammatory drug. Immunopharmacology and immunotoxicology, 2015. 37(6): p. 535-540.
Fattahi, M.J., et al., Oral administration effects of β-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomedicine & Pharmacotherapy, 2018. 100: p. 495-500.
Farhang, H., et al., The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line. Current drug discovery technologies, 2019. 16(1): p. 91-95.
Hosseini, S., et al., Anti-aging effects of M2000 (β-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. Journal of basic and clinical physiology and pharmacology, 2017. 28(3): p. 249-255.
Sharifi, L., et al., The role of toll-like receptors in B-cell development and immunopathogenesis of common variable immunodeficiency. Expert review of clinical immunology, 2016. 12(2): p. 195-207.
Mirshafiey, A., et al., Anti-aging property of G2013 molecule as a novel immunosuppressive agent on enzymatic and non-enzymatic oxidative stress determinants in rat model. Current drug discovery technologies, 2016. 13(1): p. 25-33.
Mortazavi-Jahromi, S.S., et al., Anti-diabetic effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Archives of physiology and biochemistry, 2019. 125(5): p. 435-440.
Esmaeili-Bandboni, A., M.H. Javanbakht, and A. Mirshafiey, Use of miR-34a, miR-126, and miR-125a-5p expression level as diagnostic factor and therapeutic target for α-L-guluronic acid and β-D-mannuronic acid in Type-I diabetic rat models. 2020.
Qin, B., et al., MicroRNAs expression in ox-LDL treated HUVECs: MiR-365 modulates apoptosis and Bcl-2 expression. Biochemical and biophysical research communications, 2011. 410(1): p. 127-133.
Liu, H., et al., MiR-34a and miR-34c are involved in the pathogenesis of type-2 diabetes by modulating the cell cycle of pancreatic beta-cell. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016. 9(5): p. 5340-5345.
Hosseini, F., et al., Targeting of crosstalk between tumor and tumor microenvironment by β‐D mannuronic acid (M2000) in murine breast cancer model. Cancer medicine, 2017. 6(3): p. 640-650. 316
Kashefi, S., et al., The Anti-tumoral Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID on Treg Cells Frequency and MMP-2, MMP-9, CCL22 and TGFβ1 Gene Expression in Pre-surgical Breast Cancer Patients. Iranian Journal of Allergy, Asthma and Immunology, 2019. 18(1): p. 80-90.
Ahmadi, H., et al., The potent inhibitory effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on anti-cyclic citrullinated peptide antibodies, rheumatoid factor and antidsDNA antibodies in patients with rheumatoid arthritis. Current drug discovery technologies, 2017. 14(3): p. 206-214.
Fattahi, M.J., et al., Evaluation of the efficacy and safety of β-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I/II clinical trial. International Immunopharmacology, 2018. 54: p. 112-117.
Najafi, S., et al., The Effects of Mannuronic Acid on IL‐1β, IL‐17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis. The Journal of Clinical Pharmacology, 2022. 62(6): p. 762-
Cho, S.-G., et al., Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. Journal of Biological Chemistry, 2001. 276(16): p. 12749-12755.
Nazeri, S., et al., Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a nonsteroidal anti-inflammatory drug with immunomodulatory property. Immunopharmacology and Immunotoxicology, 2017. 39(2): p. 59-65.
Mortazavi Jahromi, S.S., et al., Inhibitory effect of G2013 molecule as a novel immunomodulatory agent, on miR-155 gene expression in HEK-Blue hTLR4 cell line. European Journal of Inflammation, 2016. 14(2): p.
Taeb, M., et al., An in vitro evaluation of anti-aging effect of guluronic acid (G2013) based on enzymatic oxidative stress gene expression using healthy individuals PBMCs. Biomedicine & Pharmacotherapy, 2017. 90: p. 262-267.
Fard, N.A., et al., Efficacy and safety of G2013 as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Iranian Journal of Public Health, 2017. 46(2): p. 216.
Sharifi, L., et al., Immunomodulatory effect of G2013 (α-L-Guluronic acid) on the TLR2 and TLR4 in human mononuclear cells. Current Drug Discovery Technologies, 2018. 15(2): p. 123-131.
Hajivalili, M., et al., G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Cellular and molecular biology, 2016. 62(4): p. 1-5.
Mirshafiey, A., et al., Evaluation of the effect of α-L-guluronic acid (G2013) on COX-1, COX-2 activity and gene expression for introducing this drug as a novel NSAID with immunomodulatory property. Recent patents on inflammation & allergy drug discovery, 2018. 12(2): p. 162-168.
Abolhassani, H., et al., Autoimmune phenotype in patients with common variable immunodeficiency. J Investig Allergol Clin Immunol, 2013. 23(5): p. 323-9.
Sharifi, L., et al., Immunomodulation of TLR2 and TLR4 by G2013 (alfa-L-Guluronic acid) in CVID Patients. International Journal of Pediatrics, 2017. 5(7): p. 5327-5337.
Afraei, S., et al., New therapeutic approach by G2013 in experimental model of multiple sclerosis. Acta Neurologica Belgica, 2015. 115(3): p. 259-266.
Hosseini, F., et al., Anti‐inflammatory and anti‐tumor effects of α-l-guluronic acid (G2013) on cancerrelated inflammation in a murine breast cancer model. Biomedicine & Pharmacotherapy, 2018. 98: p. 793-
Noorbakhsh, S.M., et al., Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions. Immunopharmacology and Immunotoxicology, 2019. 41(6): p. 586-590.
Khadem Azarian, S., et al., A randomized clinical trial for the assessment of the efficacy and safety of guluronic acid (G2013) in patients with rheumatoid arthritis. Immunopharmacology and immunotoxicology, 2019. 41(1): p. 95-101.
Khadem Azarian, S., et al., Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients. Immunopharmacology and Immunotoxicology, 2020. 42(1): p. 22-27.
Bakhtiari, T., et al., Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients. Iranian Journal of Allergy, Asthma and Immunology, 2019: p. 1-10.
Mortazavi-Jahromi, S.S., et al., Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties. Immunologic research, 2019. 67(1): p. 108-115.
Nazeri, S., et al., The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial. Pharmacological Reports, 2019. 71(3): p. 393-398.
Tavasolian P, Sharifi L, Aghamohammadi A, Noorbakhsh F, Sanaei R, Shabani M, et al. Toll-like receptors pathway in common variable immune deficiency (CVID) and X-linked agammaglobulinemia (XLA). Eur Cytokine Netw. 2018;29(4):153-8.
Sharifi L, Aghamohammadi A, Rezaei N, Yazdani R, Rezaei F, Bokaie S, et al. Interleukin-1β and interleukin-6 in Common Variable Immunodeficiency and their association with subtypes of B cells and response to the Pneumovax-23 vaccine. Eur Cytokine Netw. 2019;30(4):123-9.
Saadat P, Noorbakhsh M, Beladi Moghadam N, Babarykin D, Smirnova G, Najafi S, et al. Efficacy and Safety of Guluronic Acid (G2013) in a Randomized, Controlled Phase II Clinical Trial on Patients with Multiple Sclerosis. Biomed J Sci & Tech Res, BJSTR. 2022.47.007552.
Rezaieyazdi Z, Farooqi A, Soleymani-Salehabadi H, Ahmadzadeh A, Aslani M, Omidian S, et al. International multicenter randomized, placebo-controlled phase III clinical trial of β-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology. 2019;27(5):911-21.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mahsa Taeb, Mehdi Rahmani, Laleh Sharifi, Abbas Mirshafiey
This work is licensed under a Creative Commons Attribution 4.0 International License.
